EUCTR2016-003370-40-IT进行中（未招募）1 期
A Phase 3, Double-blind, Randomized, Placebo-controlled, MulticenterStudy of GBT440 Administered Orally to Patients With Sickle Cell Disease
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 274
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female study participants with Sickle Cell Disease:
- •Documentation of SCD genotype (HbSS, HbSC, HbSß thalassemia or
- •other sickle cell syndrome variants) may be based on history of
- •laboratory testing or must be confirmed by
- •laboratory testing during screening
- •2. Participants have had at least 1 episode of VOC in the past 12 months.
- •For study eligibility, VOC is defined as a previously documented episode
- •of ACS or acute painful crisis (for which there was no explanation other
- •than VOC) which required prescription or healthcare professional instructed
- •use of analgesics for moderate to severe pain (documentation
- •must exist in the patient medical record prior to Screening)
- •3. Age 12 to 65 years
- •4. Hemoglobin (Hb) =6.0 and =10.5 g/dL during screening
- •5. Absolute reticulocyte count and % reticulocyte count must be >1.5 ×
- •ULN during Screening
- •6. For participants taking hydroxyurea (HU), the dose of HU (mg/kg)
- •must be stable for at least 3 months prior to signing the ICF and with no
- •anticipated need for dose adjustments during the study, in the opinion of the Investigator
- •7. Participants must demonstrate 75% compliance with ePRO measure
- •completion to be enrolled (participants will be given an ePRO device for
- •at least 28 days during Screening; participants who are 60 to 74%
- •compliant can re-screen once with Investigator approval; re-screening is
- •not allowed for participants who are <60% compliant)
- •8. Participants, who if female and of child bearing potential, are using
- •highly effective methods of contraception from study start to 3 months
- •after the last dose of study drug, and who if male are willing to use
- •barrier methods of contraception, from study start to 3 months after the
- •last dose of study drug
- •9. Participant has provided documented informed consent or assent (the
- •informed consent form [ICF] must be reviewed and signed by each
- •participant; in the case of pediatric participants, both the consent of the
- •participant's legal representative or legal guardian, and the participant's
- •assent must be obtained)
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 290
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. More than 10 VOCs within the past 12 months that required a hospital,
- •emergency room or clinic visit
- •2. Female who is breast feeding or pregnant
- •3. Patients who are receiving regularly scheduled blood (RBC)
- •transfusion therapy (also termed chronic, prophylactic, or preventive
- •transfusion) or have received a RBC transfusion for any reason within 28
- •days of signing the ICF
- •4. Hospitalized for sickle cell crisis or other vaso-occlusive event within
- •14 days of signing the ICF
- •(i.e., a vaso-occlusive event cannot be within 14 days prior to ICF)
- •5. Hepatic dysfunction characterized by alanine aminotransferase (ALT)
- •6. Participants with clinically significant bacterial, fungal, parasitic or
- •viral infection which require therapy:
- •Participants with acute bacterial infection requiring antibiotic use
- •should delay screening/enrollment until the course of antibiotic therapy
- •has been completed.
- •Participants with known active hepatitis A, B, or C or who are known to
- •be human immunodeficiency virus (HIV) positive
- •7. Severe renal dysfunction (estimated glomerular filtration rate at the
- •Screening visit; calculated by the central laboratory) <30mL/min/1.73²
- •or on chronic dialysis
- •8. History of malignancy within the past 2 years prior to treatment Day 1
- •requiring chemotherapy and/or radiation (with the exception of local
- •therapy for non-melanoma skin malignancy)
- •9. History of unstable or deteriorating cardiac or pulmonary disease
- •within 6 months prior to consent including but not limited to the
- •Unstable angina pectoris or myocardial infarction or elective coronary
- •intervention
- •Congestive heart failure requiring hospitalization
- •Uncontrolled clinically significant arrhythmias
- •10. Any condition affecting drug absorption, such as major surgery
- •involving the stomach or small intestine (prior cholecystectomy is
- •acceptable)
- •11. Participated in another clinical trial of an investigational agent (or
- •medical device) within 30 days or 5 half-lives of date of informed
- •consent, whichever is longer, or is currently participating in another trial
- •of an investigational agent (or medical device) 12. Inadequate venous access as determined by the Investigator/site
- •13. Medical, psychological, or behavioral conditions, which, in the
- •opinion of the Investigator, may confound study interpretation, interfere
- •with compliance, or preclude informed consent
研究者
相似试验
招募中
1 期
A study to determine if ALXN2220 is effective, safe, and tolerable in adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).CTIS2023-506669-70-00Alexion Pharmaceuticals Inc.982
进行中（未招募）
1 期
Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCCResectable high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC)MedDRA version: 20.0 Level: PT Classification code 10041823 Term: Squamous cell carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001974-76-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.570
进行中（未招募）
1 期
Phase 3 Study of Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)Recurrent, Platinum-Sensitive Ovarian CancerMedDRA version: 21.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-005099-21-NOMersana Therapeutics, Inc.581
进行中（未招募）
1 期
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to study the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents = 6 to <18 years of ageAcute Migraine (with or without aura)MedDRA version: 20.0Level: PTClassification code 10052787Term: Migraine without auraSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10027607Term: Migraine with auraSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: HLTClassification code 10027603Term: Migraine headachesSystem Organ Class: 10029205 - Nervous system disordersEUCTR2021-005246-15-PLPfizer Inc.640
进行中（未招募）
1 期
Combining chemotherapy with either the medication entospletinib or a placebo for adults with acute myeloid leukemia that has a nucleophosmin-1 abnormalityMedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864Acute Myeloid LeukemiaEUCTR2021-000761-33-PLKronos Bio, Inc.180